- Home
- RFIL vs KZIA Comparison
RFIL vs KZIA Comparison
Compare RFIL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | KZIA |
|---|---|---|
| Founded | 1979 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 154.9M |
| IPO Year | 1996 | 2002 |
Fundamental Metrics
Financial Performance| Metric | RFIL | KZIA |
|---|---|---|
| Price | $13.25 | $13.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $11.25 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 231.7K | 200.4K |
| Earning Date | 06-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $9.65 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | $187.86 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $5.54 | $4.86 |
| 52 Week High | $22.30 | $17.40 |
Technical Indicators
Market Signals| Indicator | RFIL | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 50.25 |
| Support Level | $13.10 | $11.39 |
| Resistance Level | $13.50 | $14.74 |
| Average True Range (ATR) | 0.83 | 1.07 |
| MACD | 0.28 | 0.08 |
| Stochastic Oscillator | 82.62 | 48.05 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.